Aclarion Taps PRIA for U.S. Market Access of AI Nociscan Following UK Payer Approvals
ACON•Aclarion launched a U.S. Market Access Program with PRIA Healthcare to secure reimbursement of its AI-driven Nociscan platform for chronic low back pain, leveraging approvals from three of the top four UK private insurers. PRIA will handle payer engagement, prior authorizations and appeals management to streamline coverage and expand access.
1. U.S. Market Access Program Launch
Aclarion and PRIA Healthcare have initiated a Market Access Program designed to drive reimbursement and commercial adoption of Nociscan across U.S. healthcare systems. This marks Aclarion’s first structured effort to translate its clinical evidence into payer coverage pathways and scalable market entry.
2. PRIA’s Reimbursement Expertise
PRIA Healthcare will lead payer engagement, prior authorization support and appeals management under the program. These services aim to reduce administrative barriers for physicians and hospitals, while gathering real-world utilization insights to inform future coverage discussions.
3. Building on UK Approval Milestone
Nociscan has secured coverage from three of the top four private insurers in the United Kingdom, demonstrating clinical and economic value for chronic low back pain management. These approvals underpin Aclarion’s engagement strategy with U.S. payers, reinforcing evidence-driven discussions on nationwide access.
